Last edition
News about "Alumis "
Alumis and Kaken Pharmaceutical to Develop ESK-001 in Dermatology in Japan
Under the terms of the agreement, Alumis will receive USD 40 million in upfront and near-term co-development payments from 2025 to 2026, with the potential to earn up to approximately USD 140 million in additional payments based on the achievement of milestones, and field option payments.
Alumis | 28/03/2025 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members